Former Alere and LumiraDx R&D Chief Nigel Lindner Joins CLEU Diagnostics to Launch Revolutionary LabSimple Diagnostic Platform
PHILADELPHIA--(BUSINESS WIRE)--CLEU Diagnostics, the company reimagining comprehensive clinical laboratory testing has expanded its team with the addition of Nigel Lindner, PhD as Chief Innovation Officer. Dr. Lindner brings over three decades of experience in advancing innovation in diagnostics, previously as Global Head of R&D at Alere, CEO of Swiss Precision Diagnostics, and CIO at LumiraDx. “We are incredibly excited about the opportunity to work closely with Dr. Lindner to validate and.
businesswire.com
Read More
Why Is LumiraDx (LMDX) Stock Down 13% Today?
LumiraDx (NASDAQ: LMDX ) stock is taking a beating on Monday as investors prepare for the point-of-care diagnostics company's shares to be suspended tomorrow. LumiraDx notes that shares of LMDX are going to be suspended from the Nasdaq Exchange at the start of business on Tuesday.
investorplace.com
Read More
LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th
LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards.
globenewswire.com
Read More
Roche to buy part of LumiraDx diagnostics platform for $295 million
Swiss drugmaker Roche said on Friday it has agreed to buy LumiraDx's Point of Care diagnostics platform business for about $295 million.
reuters.com
Read More
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche.
globenewswire.com
Read More
Best Penny Stocks Today? 3 To Watch Under $4 Now
Penny stocks can offer traders massive profits through their sheer price volatility. With prices below $5 per share, these tiny companies allow you to snap up many shares.
pennystocks.com
Read More
Penny Stocks To Buy? 4 Under $5 To Watch Right Now
When it comes to finding penny stocks to buy, there are plenty of things you'll need to make note of. Sure, broader stock market news trends don't directly influence cheap stocks.
pennystocks.com
Read More
LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal
LONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (Nasdaq: LMDX)(the “Company”) received a notice (“Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that on April 21, 2023, the Staff had notified the Company that the bid price of its listed securities had closed at less than $US1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). Therefore, in accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until October 18, 2023, to regain compliance with the Minimum Bid Price Requirement. The Notice states that because the Company has not regained compliance with the Minimum Bid Price Requirement, its securities are now subject to delisting from The Nasdaq Global Market.
globenewswire.com
Read More
Why Is LumiraDx (LMDX) Stock Down 35% Today?
LumiraDx (NASDAQ: LMDX ) stock is falling on Tuesday as the point-of-care diagnostics company's shares retreat from a rally on Monday. Investors will note that LMDX stock underwent a 217% rally on Monday.
investorplace.com
Read More
Why Is LumiraDx (LMDX) Stock Up 323% Today?
LumiraDx (NASDAQ: LMDX ) stock is taking off on Monday with a new partnership with AstraZeneca (NASDAQ: AZN ) behind its rally. This collaboration has LumiraDx working together with AstraZeneca and Everton in the Community to set up the first community-based heart and lung screening hub in England.
investorplace.com
Read More
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
benzinga.com
Read More
LumiraDx Limited (LMDX) Loses -25.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
LumiraDx Limited (LMDX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
zacks.com
Read More
What Makes LumiraDx Limited (LMDX) a New Buy Stock
LumiraDx Limited (LMDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Read More
LumiraDx Limited (LMDX) Q2 2023 Earnings Call Transcript
LumiraDx Limited (NASDAQ:LMDX ) Q2 2023 Earnings Call Transcript August 24, 2023 8:30 AM ET Company Participants Melissa Garcia - Vice President Corporate Counsel Ron Zwanziger - Chairman & Chief Executive Officer Dorian LeBlanc - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Jeffrey Cohen - Ladenburg Thalmann Andrew Cooper - Raymond James Mark Massaro - BTIG Operator Good day and thank you for standing by. Welcome to the LumiraDx Second Quarter 2023 Earnings Conference Call.
seekingalpha.com
Read More
LumiraDx Limited (LMDX) Reports Q2 Loss, Misses Revenue Estimates
LumiraDx Limited (LMDX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.58 per share a year ago.
zacks.com
Read More
LumiraDx Reports Second Quarter 2023 Results
LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023.
globenewswire.com
Read More
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24
LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.
globenewswire.com
Read More
LumiraDx's Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests
Axonlab Secures Exclusive Distribution Rights in Swiss Market and Additional Non-Exclusive Distribution Rights in Germany Axonlab Secures Exclusive Distribution Rights in Swiss Market and Additional Non-Exclusive Distribution Rights in Germany
globenewswire.com
Read More
Why Is LumiraDx (LMDX) Stock Up 30% Today?
LumiraDx (NASDAQ: LMDX ) stock is heading higher on Wednesday morning after the company received approval for its Covid and RSV tests. The U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) gave its approval to the company's test through its Coronavirus Test Device Approvals (CTDA) process.
investorplace.com
Read More
Best Penny Stocks to Buy Under $5? 4 To Watch Now
Penny stocks are shares of companies that trade for less than $5. That's the standard definition of the term, but most traders who're familiar with the idea generally focus on cheaper stocks.
pennystocks.com
Read More
LumiraDx Limited (LMDX) Reports Q1 Loss, Tops Revenue Estimates
LumiraDx Limited (LMDX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.22 per share a year ago.
zacks.com
Read More
LumiraDx Limited (LMDX) Reports Q4 Loss, Tops Revenue Estimates
LumiraDx Limited (LMDX) delivered earnings and revenue surprises of -68.42% and 7.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
zacks.com
Read More
LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21
LONDON, March 14, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21st, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.
globenewswire.com
Read More
LumiraDx to Present at Raymond James Institutional Investors Conference
LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that Chief Financial Officer, Dorian LeBlanc, will be presenting at the Raymond James Institutional Investors Conference on Tuesday, March 7th, 2023 at 4:35pm ET. Webcast link below.
globenewswire.com
Read More
LumiraDx Limited (LMDX) Q3 2022 Earnings Call Transcript
LumiraDx Limited (NASDAQ:LMDX ) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET Company Participants Colleen McMillen - Vice President, Communications Ron Zwanziger - Chairman and CEO Dorian LeBlanc - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Tallman Andrew Cooper - Raymond James Operator Good day and thank you for standing by. Thank you for joining LumiraDx Third Quarter 2022 Earnings Conference Call.
seekingalpha.com
Read More
LumiraDx Limited (LMDX) Reports Q3 Loss, Tops Revenue Estimates
LumiraDx Limited (LMDX) delivered earnings and revenue surprises of -56.67% and 46.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
zacks.com
Read More
LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter financial results on Wednesday, November 9th, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8:00 AM Eastern Time to review the financial results and business highlights.
globenewswire.com
Read More
LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance
Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic” Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic”
globenewswire.com
Read More
LumiraDx Limited's (LMDX) CEO Ron Zwanziger on Q2 2022 Results - Earnings Call Transcript
LumiraDx Limited (NASDAQ:LMDX ) Q2 2022 Earnings Conference Call August 18, 2022 8:00 AM ET Company Participants Colleen McMillen - Vice President, Communications Ron Zwanziger - Chairman and CEO Dorian LeBlanc - Chief Financial Officer Pooja Pathak - Chief Product Officer Conference Call Participants Vijay Kumar - Evercore ISI Jeffrey Cohen - Ladenburg Mark Massaro - BTIG Operator Good day. And welcome to the LumiraDx Second Quarter 2022 Earnings Call.
seekingalpha.com
Read More
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18
LONDON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 18th, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8:00 AM Eastern Time to review the financial results and business highlights.
globenewswire.com
Read More
Why LumiraDx Stock Is Crashing Today
The company announced the share price of its public stock offering.
fool.com
Read More
Why LumiraDx Shares Are Rising Today
LumiraDx Ltd (NASDAQ: LMDX) shares are trading higher by 10.31% at $4.28 after the company announced it achieved CE Mark for two new Fast Lab Solutions molecular tests, including Dual-Target SARS-CoV-2 STAR Complete and SARS-CoV-2 & Flu A/B RNA STAR Complete. LumiraDx says the SARS-.
benzinga.com
Read More
LumiraDx's (LMDX) CEO Ron Zwanziger On Q1 2022 Results - Earnings Call Transcript
LumiraDx Ltd (NASDAQ:LMDX ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Colleen McMillen – Vice President-Communications Ron Zwanziger – Chairman and Chief Executive Officer Dorian LeBlanc – Chief Financial Officer Pooja Pathak – Chief Product Officer Conference Call Participants Vijay Kumar – Evercore ISI Jeffrey Cohen – Ladenburg Thalmann Andrew Cooper – Raymond James Operator Hello, and welcome to LumiraDx First Quarter 2022 Earnings Call. All participants will be in the listen-only mode.
seekingalpha.com
Read More
LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 11
LONDON , April 29, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its first quarter financial results on Wednesday, May 11, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 4:30 PM Eastern Time to review the financial results and business highlights.
prnewswire.com
Read More
Good Stocks To Buy Right Now? 4 Health Care Stocks For Your List
Could health care stocks be the top picks in the stock market this week?
stockmarket.com
Read More
LumiraDx Limited (LMDX) CEO Ron Zwanziger On Q4 2021 Results - Earnings Call Transcript
LumiraDx Limited (LMDX) CEO Ron Zwanziger On Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
Read More
LumiraDx to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Quarterly Conference Call on March 10
LONDON, March 3, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2021 financial results on Thursday, March 10, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8 AM Eastern Time to review the financial results and business highlights.
prnewswire.com
Read More
Wall Street Analysts Believe LumiraDx Limited (LMDX) Could Rally 54%: Here's is How to Trade
The mean of analysts' price targets for LumiraDx Limited (LMDX) points to a 53.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
zacks.com
Read More
LumiraDx Limited's (LMDX) CEO Ron Zwanziger On Q3 2021 Results - Earnings Call Transcript
LumiraDx Limited's (LMDX) CEO Ron Zwanziger On Q3 2021 Results - Earnings Call Transcript
seekingalpha.com
Read More
LumiraDx to Announce Third Quarter 2021 Financial Results and Host Quarterly Conference Call on November 10
LONDON, Nov. 2, 2021 /PRNewswire/ -- LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter 2021 financial results on Wednesday, November 10, 2021. On the day of the release, LumiraDx will host a conference call and webcast at 8 AM Eastern Time to review the financial results and business highlights.
prnewswire.com
Read More
Why Are LumiraDx Shares Trading Higher Today?
LumiraDx (NASDAQ:LMDX) has received emergency use approval by India's Central Drugs Standard Control Organisation for its SARS-CoV-2 Antigen test. The test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application.
benzinga.com
Read More
Here is how LumiraDx is making COVID-19 testing easier
LumiraDx (NASDAQ: LMDX) has received emergency user approval for the SARS-CoV-2 Antigen test in India from the Central Drugs Standard Organisation. The diagnostic Antigen test is designed to detect antigen nucleocapsid protein from nasal swab, and results are available within 12 minutes of the sample application.
invezz.com
Read More
LMDX Stock: Why It Substantially Increased Today
The stock price of LumiraDx (NASDAQ: LMDX) increased by over 30% pre-market today. This is why it happened.
pulse2.com
Read More